Current Report Filing (8-k)
12 April 2017 - 4:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
April 10, 2017
LION BIOTECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in
Charter)
Nevada
|
(State of Incorporation)
|
|
000-53127
|
|
75-3254381
|
Commission File Number
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
999 Skyway Road, Suite 150
|
|
|
San Carlos, California
|
|
94070
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(650) 260-7120
(Registrant’s Telephone Number,
Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425).
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12).
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
Item
8.01 Other Events
Lion Biotechnologies, Inc. (“we”
or “us”) previously disclosed that the Securities and Exchange Commission (“SEC”) was conducting an investigation
(initially designated as “
In the Matter of Galena Biopharma, Inc.
” File No. HO 12346 and now known as “
In
the Matter of Certain Stock Promotions
”) and that we were a part of that investigation. The SEC’s investigation,
in part, involved the conduct of our former Chief Executive Officer, Manish Singh, during the period between September 2013 and
April 2014, and the failure by authors of certain articles about this company to disclose that they were compensated by one of
our former investor relations firms. We also previously disclosed that we submitted an offer of settlement to the SEC, as well
as the terms of the proposed settlement.
On April 10, 2017, the SEC announced settlements
with us and with other public companies and unrelated parties in the
In the Matter of Certain Stock Promotion
investigation.
The announcement can be viewed at the SEC’s website at http://www.sec.gov. Our settlement with the SEC is consistent with
our previously disclosed settlement offer (including in our Form 10-K that we filed with the SEC on March 9, 2017), and consists
of the following: (i) We agreed, without admitting or denying the findings by the SEC, to the entry of an administrative order
that requires us to cease and desist from committing or causing any violations and any future violations of Sections 5(b), 17(a),
and 17(b) of the Securities Act of 1933, and of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder,
and (ii) we agreed to pay $100,000 as a civil money penalty. We also agreed to adopt certain internal controls with respect to
our investor relations/public relations activities.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: April 11, 2017
|
LION BIOTECHNOLOGIES, INC.
|
|
|
|
|
|
By:
/s/ GREGORY SCHIFFMAN
|
|
Gregory Schiffman, Chief Financial Officer
|
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024